Ruxolitinib for myelofibrosis therapy: Current context, pros and cons

A. Pardanani

doi:10.1038/leu.2012.21

Ruxolitinib for myelofibrosis therapy: Current context, pros and cons

A. Pardanani

Hematology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	1449-1451
Number of pages	3
Journal	Leukemia
Volume	26
Issue number	7
DOIs	https://doi.org/10.1038/leu.2012.21
State	Published - Jul 2012

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2012.21

Cite this

@article{614529f8daac4875bf0fb90cd86bdb2f,

title = "Ruxolitinib for myelofibrosis therapy: Current context, pros and cons",

author = "A. Pardanani",

year = "2012",

month = jul,

doi = "10.1038/leu.2012.21",

language = "English (US)",

volume = "26",

pages = "1449--1451",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Ruxolitinib for myelofibrosis therapy

T2 - Current context, pros and cons

AU - Pardanani, A.

PY - 2012/7

Y1 - 2012/7

UR - http://www.scopus.com/inward/record.url?scp=84863781835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863781835&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.21

DO - 10.1038/leu.2012.21

M3 - Review article

C2 - 22285996

AN - SCOPUS:84863781835

SN - 0887-6924

VL - 26

SP - 1449

EP - 1451

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Ruxolitinib for myelofibrosis therapy: Current context, pros and cons

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this